Compugen Ltd. (CGEN)
NASDAQ: CGEN · Real-Time Price · USD
1.650
-0.020 (-1.20%)
At close: Feb 13, 2026, 4:00 PM EST
1.640
-0.010 (-0.61%)
After-hours: Feb 13, 2026, 6:09 PM EST
Compugen Revenue
Compugen had revenue of $1.89M in the quarter ending September 30, 2025, a decrease of -88.96%. This brings the company's revenue in the last twelve months to $6.90M, down -88.47% year-over-year. In the year 2024, Compugen had annual revenue of $27.86M, down -16.72%.
Revenue (ttm)
$6.90M
Revenue Growth
-88.47%
P/S Ratio
22.04
Revenue / Employee
$93,284
Employees
74
Market Cap
154.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.86M | -5.60M | -16.72% |
| Dec 31, 2023 | 33.46M | 25.96M | 346.12% |
| Dec 31, 2022 | 7.50M | 1.50M | 25.00% |
| Dec 31, 2021 | 6.00M | 4.00M | 200.00% |
| Dec 31, 2020 | 2.00M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | 17.80M | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | 712.00K | -8.57M | -92.33% |
| Dec 31, 2015 | 9.28M | -3.09M | -24.99% |
| Dec 31, 2014 | 12.37M | 8.82M | 248.46% |
| Dec 31, 2013 | 3.55M | 3.31M | 1,366.53% |
| Dec 31, 2012 | 242.00K | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | 1.12M | 865.00K | 346.00% |
| Dec 31, 2009 | 250.00K | -88.00K | -26.04% |
| Dec 31, 2008 | 338.00K | 158.00K | 87.78% |
| Dec 31, 2007 | 180.00K | -35.00K | -16.28% |
| Dec 31, 2006 | 215.00K | -431.00K | -66.72% |
| Dec 31, 2005 | 646.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.07M |
| Zentalis Pharmaceuticals | 26.87M |
| ProQR Therapeutics | 18.86M |
| Caribou Biosciences | 9.30M |
| Cibus | 3.79M |
| Rani Therapeutics Holdings | 1.20M |
| Adagene | 103.20K |
CGEN News
- 3 days ago - Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors - PRNewsWire
- 2 months ago - Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million - PRNewsWire
- 3 months ago - Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Compugen Reports Third Quarter 2025 Results - PRNewsWire
- 3 months ago - Compugen to Participate in Stifel 2025 Healthcare Conference - PRNewsWire
- 3 months ago - Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 - PRNewsWire
- 4 months ago - Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 - PRNewsWire
- 4 months ago - Compugen to Present at SITC 2025 - PRNewsWire